Silencing the BRRIAR promoter not only reduces its expression but also diminishes enhancer cluster activity, leading to downregulation of BHLHE40. This suggests that BRRIAR transcription is required for the full enhancer activity in a subset of ER + breast tumors. This evidence concerns the gene BHLHE40 and breast neoplasm.